A Dose-Escalating Phase I/II Study in Patients with RAS-Mutated Metastatic Colorectal Cancer to Investigate Safety and Clinical Activity of the Triple Combination of: MEK-inhibitor binimetinib, Pan-EGFR inhibitor lapatinib and the Microtubule Targeting Agent (MTA) vinorelbine

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Binimetinib (Primary) ; Lapatinib (Primary) ; Vinorelbine (Primary)
Indications Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms RASTRIC trial

Most Recent Events

12 Sep 2023 Planned number of patients changed from 36 to 50.
21 Mar 2022 Planned number of patients changed from 40 to 36.
27 Aug 2021 Planned number of patients changed from 39 to 40.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight